Auranofin
- Atc Codes:M01CB03
- CAS Codes:34031-32-8
- PHARMGKB ID:34031-32-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ridaura; Finland: Ridaura; Germany: Ridaura; Greece: Ridaura; Ireland: Ridaura; Italy: Ridaura; Luxembourg: Ridaura; Portugal: Ridaura; Spain: Ridaura; Sweden: Ridaura; UK: Ridaura.
North America
Canada: Ridaura; USA: Ridaura.
Asia
Japan: Grelyse, Ridaura, Rizast.
Drug combinations
Chemistry
Auranofin: C~20~H~34~AuO~9~PS. Mw: 678.48. (1) Gold, (2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranosato-S)(triethylphosphine)-; (2)(1-Thio-β-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate. CAS-34031-32-8 (1976).
Pharmacologic Category
Gold Compounds. Disease-modifying Antirheumatic Drugs. Biologic Response Modifiers. (ATC-Code: M01CB03).
Mechanism of action
Gold is taken up by macrophages, which results in inhibition of phagocytosis and lysosomal membrane stabilization. Other actions observed are decreased serum rheumatoid factor and alterations in immunoglobulins.
Therapeutic use
Active stage of classic or definite rheumatoid arthritis. Psoriatic arthritis. Pemphigus.
Pregnancy and lactiation implications
Contraindicated during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to auranofin or any component of the formulation. Renal disease. History of blood dyscrasias. Congestive heart failure. Exfoliative dermatitis. Necrotizing enterocolitis. History of anaphylactic reactions.
Warnings and precautions
Gold toxicity may be associated with significant toxicity involving dermatologic (dermatitis and lesions of the mucous membranes, pruritus), gastrointestinal (persistent diarrhea, stomatitis, and enterocolitis), hematologic (depressed hemoglobin, leukocytes, granulocytes, or platelets), pulmonary (interstitial fibrosis), renal (from mild proteinuria to nephrotic syndrome), and hepatic systems (development of cholestatic jaundice). Concurrent use with ACE inhibitors may increase the risk of nitritoid reactions.